Business
Hardman Res.: R&D accelerated to advance assets
Hardman Res.: R&D accelerated to advance assets.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 6904T Avacta Group PLC 16 October 2017 \n\nHardman Res.: R&D accelerated to advance assets\nR&D accelerated to advance assets - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry, despite its limitations. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. Recent results highlighted significant progress made in its in-house therapeutic programmes with the first in-vivo studies showing safety, tolerability and efficacy of an Affimer. This adds to the de-risking of Affimer technology and attracting potential partners.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/avacta-documents/16.10.17-r-d-accelerated-to-advance-assets.pdf\n\n\n\n\nTo contact us:\n\n\nContacts:\n\n\n+44 20 7194 7622\n\n\n\n\nHardman & Co\n\n\nDr Martin Hall\n\n\[email protected]\n\n\n\n\n35 New Broad Street\n\n\nDr Dorothea Hill\n\n\[email protected] \n\n\n\n\nLondon\n\n\nDr Gregoire Pave\n\n\[email protected]\n\n\n\n\nEC2M 1NH\n\n\n \n\n\n \n\n\n\n\nFollow us on Twitter\n\n\n@HardmanandCo\n\n\nwww.hardmanandco.com \n\n\n\n\nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the ...